Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 9, 2009, Pages 3923-3928

  Sabet, Mojgan ^a   Miller, Courtney E ^a   Nolan, Thomas G ^a   Senekeo Effenberger, Kathy ^a   Dudley, Michael N ^a   Griffith, David C ^a  

^a Mpex Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; LEVOFLOXACIN; MP 376; TOBRAMYCIN; UNCLASSIFIED DRUG;

AEROSOL; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIAL SURVIVAL; DRUG EFFICACY; HUMAN; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTI-BACTERIAL AGENTS; AZTREONAM; DISEASE MODELS, ANIMAL; FEMALE; LUNG DISEASES; MICE; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 70349123019     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00268-09     Document Type: Article

References (31)

1. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
2. Clinical and Laboratory Standards Institute. 2006. Methods for dilution of antimicrobial susceptibility test for bacteria that grow aerobically, 7th ed. CLSI document M7-A7. Clinical and Laboratory Standard Institute, Wayne, PA.
3. Conway, S. P. 2005. Nebulized antibiotic therapy: the evidence. Chron. Respir. Dis. 2:35-41.
4. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
5. Cystic Fibrosis Foundation. 2000. Cystic Fibrosis Foundation patient registry annual data report, 2000. Cystic Fibrosis Foundation, Bethesda, MD.
6. Dubus, J. C., E. Bosdure, L. Bakuridze, and V. Andrieu. 2007. Nebulized drugs: the evolution? Arch. Pediatr. 14:504-506. (In French.)
7. Emerson, J., M. Rosenfeld, S. McNamara, B. Ramsey, and R. L. Gibson. 2002. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr. Pulmonol. 34:91-100.
8. Govan, J. R., and V. Deretic. 1996. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 60:539-574.
9. Griffith, D. C., E. Corcoran, D. Lofland, A. Lee, D. Cho, O. Lomovskaya, and M. N. Dudley. 2006. Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy? Antimicrob. Agents Chemother. 50:1628-1632.
10. Hoffmann, N., T. B. Rasmussen, P. O. Jensen, C. Stub, M. Hentzer, S. Molin, O. Ciofu, M. Givskov, H. K. Johansen, and N. Hoiby. 2005. Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect. Immun. 73:2504-2514.
11. Hoiby, N., E. W. Flensborg, B. Beck, B. Friis, S. V. Jacobsen, and L. Jacobsen. 1977. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand. J. Respir. Dis. 58:65-79.
12. Jumbe, N., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, C. Freeman, J. B. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and G. L. Drusano. 2003. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Investig. 112:275-285.
13. King, P., O. Lomovskaya, D. C. Griffith, D. C. Citron, J. Burns, and M. N. Dudley. 2008. Antibacterial activity of levofloxacin (MP-376) under varying in vitro conditions relevant to chronic pulmonary infection in CF patients, abstr. 358. Abstr. 22nd Annu. N. Am. Cystic Fibrosis Conf.
14. Kulczycki, L. L., T. M. Murphy, and J. A. Bellanti. 1978. Pseudomonas colonization in cystic fibrosis. A study of 160 patients. JAMA 240:30-34.
15. Levy, J., A. L. Smith, M. A. Kenny, B. Ramsey, and F. D. Schoenknecht. 1983. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J. Infect. Dis. 148:1069-1076.
16. Martinez-Solano, L., M. D. Macia, A. Fajardo, A. Oliver, and J. L. Martinez. 2008. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin. Infect. Dis. 47:1526-1533.
17. Mearns, M. B. 1972. Treatment and prevention of pulmonary complications of cystic fibrosis in infancy and early childhood. Arch. Dis. Child. 47:5-11.
18. Mendelman, P. M., A. L. Smith, J. Levy, A. Weber, B. Ramsey, and R. L. Davis. 1985. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am. Rev. Respir. Dis. 132:761-765.
19. Merlo, C. A., M. P. Boyle, M. Diener-West, B. C. Marshall, C. H. Goss, and N. Lechtzin. 2007. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 132:562-568.
20. Murphy, T. F., A. L. Brauer, K. Eschberger, P. Lobbins, L. Grove, X. Cai, and S. Sethi. 2008. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 177:853-860.
21. Pennington, J. E. 1981. Penetration of antibiotics into respiratory secretions. Rev. Infect. Dis. 3:67-73.
22. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, F. A. Wong, and M. Corrado. 1998. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob. Agents Chemother. 42:1098-1104.
23. Ramsey, B. W., M. S. Pepe, J. M. Quan, K. L. Otto, A. B. Montgomery, J. Williams-Warren, K. M. Vasiljev, D. Borowitz, C. M. Bowman, B. C. Marshall, S. Marshall, A. L. Smith, et al. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 340:23-30.
24. Remminghorst, U., and B. H. Rehm. 2006. In vitro alginate polymerization and the functional role of Alg8 in alginate production by Pseudomonas aeruginosa. Appl. Environ. Microbiol. 72:298-305.
25. Sabet, M., C. E. Miller, M. N. Dudley, and D. C. Griffith. 2008. In vivo antibacterial activity of MP-376 after aerosol or systemic administration in a chronic mouse model of pulmonary infection, abstr. 287. Abstr. 22nd Annu. N. Am. Cystic Fibrosis Conf.
26. Sabet, M., B. Saechao, J. Nguyen, K. Effenberger, O. Lomovskaya, M. N. Dudley, and D. C. Griffith. 2007. In vivo antibacterial activity of aerosol MP-376 in mouse models of pulmonary infection, abstr. 288. Abstr. 21st Annu. N. Am. Cystic Fibrosis Conf.
27. Sermet-Gaudelus, I., Y. Le Cocguic, A. Ferroni, M. Clairicia, J. Barthe, J. P. Delaunay, V. Brousse, and G. Lenoir. 2002. Nebulized antibiotics in cystic fibrosis. Paediatr. Drugs 4:455-467.
28. Smith, A. L., B. W. Ramsey, D. L. Hedges, B. Hack, J. Williams-Warren, A. Weber, E. J. Gore, and G. J. Redding. 1989. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr. Pulmonol. 7:265-271.
29. Valcke, Y., R. Pauwels, and M. Van der Straeten. 1990. The penetration of aminoglycosides into the alveolar lining fluid of rats. The effect of airway inflammation. Am. Rev. Respir. Dis. 142:1099-1103.
30. Valcke, Y., R. Pauwels, and M. Van der Straeten. 1990. Pharmacokinetics of antibiotics in the lungs. Eur. Respir. J. 3:715-722.
31. Zindani, G. N., D. D. Streetman, D. S. Streetman, and S. Z. Nasr. 2006. Adherence to treatment in children and adolescent patients with cystic fibrosis. J. Adolesc. Health 38:13-17. (Pubitemid 43016149)